No question dominates Nigerian pharmacy conversations more predictably. A young pharmacist signs on to LinkedIn, sees the relocation announcements, feels the pull. An elder closes a lecture with "the grass is not always greener." Both sides talk past each other because both are arguing identity when the question is actually arithmetic, sequencing, and self-knowledge.
This is the framework the Academy would offer — not a verdict, but a method. Use it before you resign, before you sell the car, before you pay an agent.
First, Retire the Two Bad Arguments
Against every relocation sermon: "stay and build your country" is not a career plan, and guilt is not a cost-benefit tool. The pharmacists who thrive abroad did not move to prove loyalty; they moved because the move fit their specifics.
Against every panic post: "japa at all costs" ignores real frictions — licensing exams that take years, currency costs of the process, licensing exams that must be passed while life continues, and the professional ceiling that can follow arriving as "foreign-trained" into systems with their own hierarchies.
If your decision process contains either argument, delete it. Start here.
Question 1: What, precisely, do you do — and how is it valued where you're going?
A hospital clinical pharmacist, an industrial production pharmacist, a community pharmacy owner, and a regulatory-affairs specialist face radically different relocation maths.
- Clinical/hospital pharmacists generally gain the most structural advantage abroad: clinical ladders, pharmacist prescribing in some systems, and recognised specialist tracks exist where they are still maturing at home (though the consultant pharmacist cadre is changing that calculus).
- Industrial pharmacists should look twice before leaping: Nigeria's local-manufacturing push — with local production now around half of national need and rising, and multiple new plants commissioning — is creating senior roles that simply did not exist five years ago (see where the manufacturing jobs will be).
- Community pharmacy owners are usually trading equity for salary. Owning even a modest pharmacy's upside is different from maximising a salary; compare net present value, not monthly figures.
Question 2: Can you pass the licensing gate — with a date attached?
Every destination runs its own gate: the UK's GPhC process, the US's FPGEC-to-NAPLEX sequence, Canada's PEBC evaluation, Australia's KAPS-to-AHPRA route. Our detailed licensing guide breaks down each one.
The strategic test is simple: do you have a written timeline with exam dates and a funded budget, or a vibe? A candidate with a booked assessment is emigrating. A candidate with a saved Instagram post is dreaming. The gap between those two people is eighteen months, on average.
Question 3: What does the decision cost — and who absorbs it?
Run the full ledger, not the salary delta:
- Currency and liquidity: relocation burns savings in hard currency before the first payslip.
- Career pause: licensing windows are often low-earning seasons.
- Family capital: a spouse's career, children's schooling, ageing parents — the costs here are real even when they are not financial.
- Reversibility: which failures are recoverable? An unpassed exam can be retaken; a sold pharmacy cannot be re-bought.
Question 4: Where do you want to be at 55 — and at whose table?
The question nobody asks. If your 55-year-old self wants to have built an institution, note that the coming decade offers a rare window in Nigeria: a sector being rebuilt — regulation tightening, manufacturing scaling, the profession's apex institutions investing in leadership (this is literally why the NAPharm fellowship exists). If your 55-year-old self wants security, depth of infrastructure, and systems that function without personal heroics, the arithmetic points elsewhere. Neither answer is a character flaw.
The Framework, Compressed
- Value your specific skills in the destination market — not "pharmacists" in general.
- Attach dates and budgets to licensing — no dates, no decision.
- Price the full ledger — including who absorbs each cost.
- Project to age 55 — optimise for that table, not this month's timeline.
Score honestly, and the answer usually reveals itself. The pharmacists who suffer are not the ones who stayed or the ones who left — they are the ones who left or stayed by drift.
Whatever you choose: choose it on paper, with dates, in your own handwriting.
A Note to the Ones Who Stay — and the Ones Who Go
The Academy's stake in this debate is simple: both cohorts are the profession. Nigeria needs builders at home and ambassadors abroad, and the two must stay connected — through mentorship, through collaboration, through the kind of programmes the Academy runs. If you relocate, join our programs network and stay a node in the profession's brain, not a severed connection. If you stay, subscribe to NAPharm Insights — the policy and industry shifts that will decide your decade get analysed here first.
